24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Insulin Doesn't Prevent Diabetes in Relatives of T1DM PatientsInsulin Pill May Delay Type 1 Diabetes in SomeHealth Tip: Diabetes Affects Women DifferentlySevere Psoriasis May Make Diabetes Increasingly LikelySpinal Cord Stimulation May Reduce Neuropathic PainBrain Glucose Responses Diminish With Diabetes, ObesityRisk of Falls Up With Mild, Moderate Diabetic RetinopathyFirst-Line Metformin Use for DM Up; Sulfonylurea Use DownPoor Prognosis for Diabetic Foot SoresER- Breast CA Risk Up for African-Americans With T2DMIn 2007-2014, Glycemic Control Plateaued in Diabetes PatientsDiabetes May Be Driving High Rates of Breast Cancer in Black WomenLeisure Time Exercise Linked to Reduced Mortality in T1DMAHA: Sudden Cardiac Death Risk Up for Young With DiabetesYounger People With Diabetes Have 7 Times Greater Risk of Sudden Heart DeathRisk of End-Stage Renal Disease Low With Type 1 DiabetesDrop in Incidence of End-Stage Renal Disease Due to DiabetesHealth Tip: Choosing Smarter FoodsLifestyle Changes Successfully Reduce Incidence of DiabetesNovel Method Developed for Estimating Prevalence of DiabetesNovel Artificial Pancreas Cuts HbA1c, Hypoglycemia in T1DMKidney Failure Declining Among U.S. Diabetics: CDCACE Inhibitor, Statin No Benefit for T1DM, High Albumin ExcretionMagnesium, T2DM Link Seen in Poor-Carbohydrate-Quality DietRetinal Sensitivity Linked to Cognitive Status in T2DMKidney Damage Seen in Most Patients With Long-Lasting T1DArterial Stiffness Linked to Incidence of DiabetesUndiagnosed Diabetes Accounts for Small Portion of DiabetesNew Clinical Practice Guideline for Management of T2DMDiabetes Tied to Worse Outcomes in Heart Failure PatientsStatins May Raise Odds of T2DM in Those at High RiskFinancial Incentives Up Teen Glucose Monitoring AdherenceFewer Diabetes Cases Being MissedSudden Death Most Common CV Death in T2DM/ASCVDDiabetes Ups Risk of MACE in Acute Coronary SyndromesLifestyle, Metformin Interventions Have Variable EffectsHealth Tip: Best Grains And Starchy Veggies for DiabeticsGlycemic Control Up With Oral Semaglutide in Type 2 DiabetesCommercial Weight Management Program May Help Prevent T2DDiabetes Pill Might Replace Injection to Control Blood SugarNew Screening Tool Can Identify Diabetic RetinopathyRisk Conferred by T2D Modified by HbA1c in Heart FailureNo Causal Link Between Plasma Lipids, Diabetic RetinopathyBetter Glycemic Control With Insulin Pump for Youth With T1DPump May Beat Shots for Type 1 DiabetesWhere There's Type 1 Diabetes, Celiac Disease May FollowFlu Shot Key for People With DiabetesMaking Halloween a Treat for Kids With DiabetesPay for Performance Cuts Mortality in Diabetes PatientsAddition of DPP4i to AGI Reduces HbA1c in T2DM
Links
Related Topics

Medical Disorders

Cardiometabolic Disease Staging Score Quantifies Diabetes Risk


HealthDay News
Updated: May 4th 2017

new article illustration

THURSDAY, May 4, 2017 (HealthDay News) -- For overweight and obese individuals, the Cardiometabolic Disease Staging (CMDS) score can quantify the risk of diabetes and predict the effectiveness of weight-loss therapy for preventing diabetes, according to research published online April 28 in Diabetes Care.

Fangjian Guo, M.D., Ph.D., from the University of Texas Medical Branch in Galveston, and W. Timothy Garvey, M.D., from the University of Alabama at Birmingham, pooled data from 3,040 overweight and obese participants in three randomized trials examining the efficacy and safety of phentermine/topiramate extended release (ER) for weight loss. Overweight/obese adult patients were treated with a lifestyle intervention and randomized to either placebo or once-daily phentermine/topiramate ER in these trials. Baseline clinical data were used to calculate the weighted CMDS score.

The researchers found that the absolute decrease in one-year diabetes incidence rates for subjects treated with medication versus placebo was greatest, intermediate, and small for those with high-risk CMDS scores, moderate CMDS risk, and low-risk CMDS scores, respectively (10.43 to 6.29 percent, 4.67 to 2.37 percent, and 1.51 to 0.50 percent, respectively). Over a 56-week period, for participants with baseline CMDS scores of ≥60, 30 to 59, and 0 to 29, the number of participants needed to treat to prevent one new case of diabetes was 24, 43, and 120, respectively.

"CMDS can be used to quantify risk of diabetes in overweight/obese individuals and predict the effectiveness of weight-loss therapy to prevent diabetes," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)